Hepatitis C

The XGBoost machine learning model outperformed other AI and logistic regression models for predicting DAA failure, with an AUROC of 1.000 in the training dataset and 0.803 in the validation dataset.

Patients in the integrated and standard care treatment arms reported similar SCL-10 scores indicative of psychological stress and symptom burden, both at baseline and after the completion of DAA treatment.

Although the overall response rate among the cohort was 96.4%, this figure dropped as low as 66.7% when accounting for male gender, GT3 infection, cirrhosis, obesity, and non-response to previous therapy.

Response to direct-acting antiviral therapy was similar between patients with and without HBV coinfection, with most patients completing the planned course of treatment and achieving SVR, even in the case of HBV reactivation.

Investigators examined data from the Global Burden of Disease, Injuries, and Risk Factors study 2019 to describe the global, regional, and national burden of liver cancer due to hepatitis C since 1990.

Patients with lean NAFLD had fewer metabolic comorbidities but maintained similar risk of NASH, cirrhosis, nonliver cancer, and mortality compared to their overweight and obese counterparts.

IVF treatment and pregnancy outcomes were not significantly different between patients with and without liver disease who received assisted reproductive technology treatment.

Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.

More than half of study participants were enrolled in the patient portal and 98% were classified as passive users, but only moderately active use of the patient portal was associated with a reduced risk of readmission.

Although no differences were observed in the safety and efficacy of FDA-approved combination DAA therapies, female participants reported numerically more adverse events than male participants.

Results from the systematic review and meta-analysis demonstrated the positive effect of DAA therapy on overall survival, HCC-free survival, and liver function among patients with HCV decompensated cirrhosis compared to a non-DAA control group.

Patients with HCV who underwent automated routine screening and the addition of a clinical pharmacist to the interdisciplinary patient care model completed treatment and achieved SVR at a greater rate than patients who were not exposed to the study intervention.

Following years of concerns about the stigmatization and inaccurate etiology of nonalcoholic fatty liver disease nomenclature, 2023 finally saw revised terminology for liver disease with the implementation of metabolic dysfunction-associated steatotic liver disease.

A cohort of patients with end-stage renal disease on maintenance hemodialysis saw a 7% reduction in HCV-viremic rate and primary infection rates as low as 0.01% following implementation of the link-to-treat program.

Just 8.5% of eligible patients were screened for hepatitis C - among them, 5.9% tested positive for HCV antibody and 3.0% had an active infection.

The seroprevalence of HCV antibody among pregnant women was significantly greater among those with opioid use disorder and HIV infection, as well as in lower-middle-income countries and those with low levels of HDI.

8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.

The ultrasound prevalence of NAFLD was 23% among a cohort of patients with IBD, with study results further identifying several clinical characteristics associated with IBD-NAFLD including age, gender, BMI, and waist circumference.

The model uses repeated measurements of longitudinal predictors as opposed to variables collected once at baseline to assess risk of HCC after SVR.

Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.

Therapy with glecaprevir/pibrentasvir (G/P) demonstrated a virologic response at posttreatment week 12 rate, which was superior to the prior efficacy threshold.

Patients with HCV-related cirrhosis remain at risk for developing liver-related and non-liver-related events after achieving sustained virologic response.

A cohort analysis shows foreign-born patients are significantly less likely to be immunized for HBV than US-born patients.

After receiving the COVID-19 vaccination, the antibody titers of patients with cirrhosis and hepatocellular carcinoma were significantly reduced compared to patients with chronic hepatitis C patients.

A new study from AASLD 2023 provides a snapshot of how the introduction of second-generation direct-acting antivirals on treatment patterns for hepatitis C.

Interim data presented at The Liver Meeting highlight the novel antigen-specific immunotherapy's potential in resolving hepatitis B.

Madhumita Premkumar, MD, discusses a nationwide, cost-efficient eradication strategy she believes could benefit Americans' efforts to curb HCV.

Findings from The Liver Meeting show the impact of acute alcoholic hepatitis on progression to severe disease and risk of death among younger populations.

Investigator Jiten P. Kothadia, MD, discusses the advent of a predictive score for alcohol relapse risk in patients with alcohol liver disease who received a liver transplant in the last year.

Phase 2b data from the AHFIRM trial is anticipated soon. Reau discusses what the agent may show in treating alcohol-associated hepatitis.